Gilead’s Coronavirus treatment drug Remdesivir meets primary end point

  • Data from National Institute of Allergy and Infectious Disease (NAID) says study of Remdesivir for treatment of coronavirus showed the antiviral had met its primary end point.
  • Results of Gilead’s SIMPLE Trial showed patients receiving a 10-day treatment achieved similar results compared to those taking a 5-day course.
  • Gilead’s stock was temporarily halted on the market as news of the development leaked.

Sources: Gilead